Bloomberg -- Human Genome Sciences Inc. may get U.S. regulatory approval next month for the first new lupus treatment in 50 years, a move that could spur acquisition offers.
Bloomberg -- Human Genome Sciences Inc. may get U.S. regulatory approval next month for the first new lupus treatment in 50 years, a move that could spur acquisition offers.